drugset / Trial / NCT00121225
Vorinostat in Treating Patients With Metastatic or Unresectable Melanoma
NaSingle-groupOpen-labelTreatment
Summary
This phase II trial is studying how well vorinostat works in treating patients with metastatic or unresectable melanoma. Vorinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
Timeline
- Start
- 2005-09
- Primary completion
- 2009-03
- Completion
- 2013-06
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Vorinostat | Small molecule | 400 mg | Oral |